Abstract
Eighteen acute nonlymphoblastic leukemia patients greater than 60 yr., 12 at diagnosis and 6 in first relapse, were treated with the association of oral Idarubicin and subcutaneous Aracytin. One patient was not evaluable. Eight out of 17 patients achieved complete remission (47%), 4 patients died in induction and 5 proved resistant to treatments. Mucocutaneous and gastrointestinal toxicity was mild. The most frequent extra-hematological complications were infections. We observed an important hepatic toxicity in 1 case.
MeSH terms
-
Administration, Oral
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Chemical and Drug Induced Liver Injury / etiology
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Drug Evaluation
-
Drug Resistance
-
Female
-
Humans
-
Idarubicin / administration & dosage
-
Idarubicin / adverse effects
-
Injections, Subcutaneous
-
Leukemia, Myeloid, Acute / drug therapy*
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Remission Induction